
    
      Phase 2a, randomized, double-blinded, placebo-controlled study to evaluate the efficacy,
      safety and tolerability of two doses of KY1005 in adults with moderate to severe atopic
      dermatitis whose disease cannot be adequately controlled with topical medications or for whom
      topical treatment is medically inadvisable.
    
  